Company
Probi AB
Headquarters: Lund, Sweden
Employees: 175
Market Cap
kr2.31 Billion
SEK as of Jan. 1, 2024
US$229.8 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. It conducts research primarily in the fields of gastrointestinal and immune health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a collaboration with àrebro University for research into exploration of novel, needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian female population. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Probi AB has the following listings and related stock indices.
Stock: OMX: PROB wb_incandescent